Granted Patent B2

US 12,269,893 · App. 15/880,978 · Granted Apr 8, 2025

Inventor: Christian Duby (Brussels, BE)

Assignee: Ablynx N.V.

C07K16/36A61K38/36A61K2039/505A61K2039/545C07K2317/24C07K2317/565C07K2317/567C07K2317/569C07K2317/76

Abstract

Claims (30)

1. A method of mitigating a symptom of and/or postponing the development of thrombotic thrombocytopenia purpura (TTP) in a human subject in need thereof, comprising:

(i) administering to said human subject a dose of 5-40 mg of a polypeptide comprising the amino acid sequence of SEQ ID NO: 1;

(ii) measuring a platelet number and an ADAMTS13 activity of said human subject; and

(iii) repeating step (i) and step (ii) at least once;

wherein further administration of said dose of 5-40 mg of the polypeptide to said human subject is stopped when the human subject has a platelet number of at least 150,000/μl and an ADAMTS13 activity of at least 50% of an ADAMTS13 reference activity on two consecutive measurements, wherein said two consecutive measurements are two to seven days apart.

2. The method according to claim 1 , wherein said polypeptide consists of the amino acid sequence of SEQ ID NO: 1.

3. The method according to claim 1 , wherein said human subject is administered 10-12 mg of said polypeptide in step (i).

4. The method according to claim 1 , wherein said dose in step (i) is administered to said human subject one time per day or two times per day.

5. The method according to claim 1 , wherein step (i) is repeated daily until the human subject has a platelet number of at least 150,000/μl and an ADAMTS13 activity of at least 50% on two consecutive measurements, wherein said two consecutive measurements are two to seven days apart.

6. The method according to claim 5 , wherein said two consecutive measurements are seven days apart.

7. The method according to claim 1 , wherein said two consecutive measurements are seven days apart.

8. The method according to claim 1 , wherein the human subject is administered 11 mg of said polypeptide in step (i).

9. A method of mitigating a symptom of and/or postponing the development of thrombotic thrombocytopenia purpura (TTP) in a human subject in need thereof, comprising:

(i) administering to said human subject a dose of 5-40 mg of a polypeptide comprising the amino acid sequence of SEQ ID NO: 1;

(ii) measuring an ADAMTS13 activity of said human subject; and

(iii) repeating step (i) and step (ii) at least once;

wherein further administration of said dose of 5-40 mg of the polypeptide to said human subject is stopped when the human subject has an ADAMTS13 activity of at least 50% of an ADAMTS13 reference activity on two consecutive measurements, wherein said two consecutive measurements are two to seven days apart.

10. The method of claim 9 , wherein said polypeptide consists of the amino acid sequence of SEQ ID NO: 1.

11. The method of claim 9 , wherein said human subject is administered 10-12 mg of said polypeptide in step (i).

12. The method of claim 9 , wherein said dose in step (i) is administered to said human subject one time per day or two times per day.

13. The method of claim 9 , wherein step (ii) further comprises measuring a platelet number of said human subject.

14. The method according to claim 9 , wherein said two consecutive measurements are seven days apart.

15. A method of mitigating a symptom of and/or postponing the development of thrombotic thrombocytopenia purpura (TTP) in a human subject in need thereof, comprising:

(i) administering to said human subject a dose of 5-40 mg of a polypeptide comprising the amino acid sequence of SEQ ID NO: 1;

(ii) measuring an ADAMTS13 activity of said human subject; and

(iii) repeating step (i) and step (ii) if said ADAMTS13 activity is lower than 50% of an ADAMTS13 reference activity on two consecutive measurements, wherein said two consecutive measurements are two to seven days apart, or stopping administration of said dose of 5-40 mg of the polypeptide to said human subject if said ADAMTS13 activity is not lower than 50% of an ADAMTS13 reference activity on two consecutive measurements, wherein said two consecutive measurements are two to seven days apart.

16. The method of claim 15 , wherein said polypeptide consists of the amino acid sequence of SEQ ID NO: 1.

17. The method of claim 15 , wherein said human subject is administered 10-12 mg of said polypeptide in step (i).

18. The method of claim 15 , wherein said dose in step (i) is administered to said human subject one time per day or two times per day.

19. The method of claim 15 , wherein step (ii) further comprises measuring a platelet number of said human subject.

Assignments (1)

Priority Claims (1)

Continuity (3)

References Cited (81)